Geke A P Hospers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3855020/publications.pdf

Version: 2024-02-01

153 papers	9,005 citations	76294 40 h-index	46771 89 g-index
155 all docs	155 docs citations	155 times ranked	11446 citing authors

#	Article	IF	Citations
1	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, The, 2015, 16, 1090-1098.	5.1	1,861
2	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 29-42.	5.1	739
3	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
4	Platelets and Granulocytes, in Particular the Neutrophils, Form Important Compartments for Circulating Vascular Endothelial Growth Factor. Angiogenesis, 2003, 6, 283-287.	3.7	442
5	Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis, 2001, 4, 91-102.	3.7	312
6	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology, 2021, 39, 1995-2004.	0.8	291
7	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 449-58.	2.0	253
8	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	5.1	242
9	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer â€“ the RAPIDO trial. BMC Cancer, 2013, 13, 279.	1.1	237
10	PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncology, The, 2013, 14, e465-e475.	5.1	173
11	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nature Medicine, 2022, 28, 535-544.	15.2	158
12	A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacological Research, 2006, 53, 89-103.	3.1	138
13	PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. Journal of Nuclear Medicine, 2012, 53, 182-190.	2.8	136
14	Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy. Annals of Surgery, 2014, 260, 786-793.	2.1	134
15	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer â€“ Results of the international randomized RAPIDO-trial. Radiotherapy and Oncology, 2020, 147, 75-83.	0.3	132
16	Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.. Current Gene Therapy, 2002, 2, 307-322.	0.9	129
17	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	15.2	121
18	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer, 2018, 18, 877.	1.1	115

#	Article	IF	Citations
19	VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. Cancer Research, 2011, 71, 143-153.	0.4	105
20	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. Journal of Clinical Oncology, 2018, 36, 268-275.	0.8	91
21	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. Journal of Clinical Oncology, 2020, 38, 4006-4006.	0.8	84
22	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 2017, 72, 156-165.	1.3	77
23	Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing. Molecular Cancer Research, 2013, 11, 1029-1039.	1.5	72
24	[11C]FMAU and [18F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. Nuclear Medicine and Biology, 2000, 27, 113-119.	0.3	67
25	Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta OncolÃ³gica, 2013, 52, 1786-1788.	0.8	67
26	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
27	Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology, 2016, 55, 1143-1145.	0.9	63
28	Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues. Oncologist, 2011, 16, 783-787.	1.9	62
29	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. Journal of Clinical Oncology, 2020, 38, 10002-10002.	0.8	57
30	Impact of Neoadjuvant Chemoradiotherapy on Postoperative Course after Curative-intent Transthoracic Esophagectomy in Esophageal Cancer Patients. Annals of Surgical Oncology, 2014, 21, 605-611.	0.7	52
31	18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. Nuclear Medicine Communications, 2006, 27, 25-30.	0.5	51
32	VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients. European Journal of Cancer, 2011, 47, 1595-1602.	1.3	51
33	Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1674-1681.	3.3	48
34	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. Journal of Nuclear Medicine, 2017, 58, 1906-1912.	2.8	48
35	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2021, 174, 641-648.	2.0	46
36	¹⁸F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. Journal of Nuclear Medicine, 2018, 59, 1212-1218.	2.8	45

#	Article	IF	Citations
37	Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using 16Î±-¹⁸F-Fluoro-17Î²-Estradiol PET/CT. Journal of Nuclear Medicine, 2015, 56, 50-55.	2.8	44
38	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2â€"Positive Esophageal Adenocarcinoma: TRAP Study. Journal of Clinical Oncology, 2020, 38, 462-471.	0.8	44
39	Different Recurrence Pattern After Neoadjuvant Chemoradiotherapy Compared to Surgery Alone in Esophageal Cancer Patients. Annals of Surgical Oncology, 2013, 20, 4008-4015.	0.7	43
40	Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 634-639.	0.6	43
41	Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. Melanoma Research, 2020, 30, 235-246.	0.6	42
42	Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. Melanoma Research, 2018, 28, 96-104.	0.6	41
43	Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiotherapy and Oncology, 2014, 112, 284-288.	0.3	40
44	Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. European Journal of Cancer, 2020, 126, 11-20.	1.3	39
45	Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Research, 2014, 16, 412.	2.2	38
46	Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer and Metastasis Reviews, 2020, 39, 999-1013.	2.7	38
47	Recommendations and Technical Aspects of 16Î±-[18F]Fluoro-17Î²-Estradiol PET to Image the Estrogen Receptor In Vivo. Clinical Nuclear Medicine, 2016, 41, 844-851.	0.7	37
48	Quantitative fluorescence endoscopy: an innovative endoscopy approach to evaluate neoadjuvant treatment response in locally advanced rectal cancer. Gut, 2020, 69, 406-410.	6.1	37
49	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer ¹⁸F-BMS-986192. Journal of Nuclear Medicine, 2020, 61, 1839-1844.	2.8	37
50	¹⁸F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. Journal of Nuclear Medicine, 2022, 63, 899-905.	2.8	36
51	Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer. Journal of Nuclear Medicine, 2020, 61, 655-661.	2.8	34
52	Development and Evaluation of Interleukin-2â€"Derived Radiotracers for PET Imaging of T Cells in Mice. Journal of Nuclear Medicine, 2020, 61, 1355-1360.	2.8	32
53	Open-label, multicentre safety study of vemurafenib inÂ3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	1.3	31
54	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. Cancers, 2019, 11, 1940.	1.7	29

#	Article	IF	Citations
55	Application of PET Tracers in Molecular Imaging for Breast Cancer. Current Oncology Reports, 2020, 22, 85.	1.8	28
56	PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. Journal of Nuclear Medicine, 2004, 45, 1437-43.	2.8	28
57	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 2020, 30, 261-267.	0.6	27
58	Realâ€world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials. International Journal of Cancer, 2020, 147, 3461-3470.	2.3	27
59	Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands. Annals of Surgical Oncology, 2013, 20, 1985-1992.	0.7	26
60	Increased risk of thromboembolism in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. American Journal of Surgery, 2014, 208, 215-221.	0.9	26
61	Residual Tumor After Neoadjuvant Chemoradiation Outside the Radiation Therapy Target Volume: A New Prognostic Factor for Survival in Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 845-852.	0.4	23
62	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4369-4376.	3.3	23
63	Metastatic Uveal Melanoma: Treatment Strategies and Survivalâ€"Results from the Dutch Melanoma Treatment Registry. Cancers, 2019, 11, 1007.	1.7	22
64	Improvement ofIn VivoTransfer of Plasmid DNA in Muscle: Comparison of Electroporation versus Ultrasound. Drug Delivery, 2007, 14, 273-277.	2.5	21
65	Value of¹⁸F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study. Journal of Nuclear Medicine, 2021, 62, 1214-1220.	2.8	21
66	Clinical Validity of 16Îą-[¹⁸F]Fluoro-17Î²-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3642-3652.	0.8	21
67	Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer â€“ The RAPIDO trial. Radiotherapy and Oncology, 2022, 171, 69-76.	0.3	20
68	Scintigraphic Imaging of HSVtk Gene Therapy. Current Pharmaceutical Design, 2002, 8, 1435-1450.	0.9	19
69	Disparities in survival of stomach cancer among different socioeconomic groups in North-East Netherlands. Cancer Epidemiology, 2011, 35, 413-416.	0.8	19
70	CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. Radiotherapy and Oncology, 2015, 117, 152-158.	0.3	19
71	Synthesis and Evaluation of the Estrogen Receptor Î²â€“Selective Radioligand 2-¹⁸F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with 16Îą-¹⁸F-Fluoro-17Î²-Estradiol. Journal of Nuclear Medicine, 2017, 58, 554-559.	2.8	19
72	18F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer. Clinical Nuclear Medicine, 2017, 42, 612-614.	0.7	19

#	Article	IF	Citations
73	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. European Journal of Cancer, 2022, 167, 70-80.	1.3	19
74	Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. Radiotherapy and Oncology, 2014, 113, 188-192.	0.3	18
75	Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis. EJNMMI Research, 2018, 8, 101.	1.1	18
76	The unfavorable effects of <scp>COVID</scp>â€19 on Dutch advanced melanoma care. International Journal of Cancer, 2022, 150, 816-824.	2.3	18
77	18Fâ€Fluorodeoxyglucose Positron Emission Tomography for Monitoring Response to Sorafenib Treatment in Patients with Hepatocellular Carcinoma. Oncologist, 2008, 13, 734-735.	1.9	17
78	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. Journal of Immunotherapy, 2020, 43, 256-264.	1.2	17
79	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. Journal of Clinical Oncology, 2017, 35, 9524-9524.	0.8	17
80	Evaluation of [18F]FHPG as PET tracer for HSVtk gene expression. Nuclear Medicine and Biology, 2003, 30, 651-660.	0.3	16
81	Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: Case report and review of the literature. European Journal of Cancer, 2013, 49, 3850-3855.	1.3	16
82	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 2020, 12, 2072.	1.7	16
83	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 2021, 124, 1222-1230.	2.9	16
84	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	0.8	16
85	Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 15.	1.8	15
86	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers, 2020, 12, 1003.	1.7	15
87	CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. Current Pharmaceutical Design, 2015, 21, 2276-2283.	0.9	15
88	Treatment of locally advanced rectal cancer. Surgical Oncology, 2004, 13, 137-147.	0.8	14
89	Molecular imaging for monitoring treatment response in breast cancer patients. European Journal of Pharmacology, 2013, 717, 2-11.	1.7	14
90	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. ESMO Open, 2020, 5, e000945.	2.0	14

#	Article	IF	Citations
91	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands â€“ A nationwide population-based study. European Journal of Cancer, 2020, 137, 127-135.	1.3	14
92	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatology International, 2021, 15, 510-519.	1.9	14
93	Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets. Methods in Molecular Biology, 2010, 596, 15-31.	0.4	13
94	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 2019, 107, 175-185.	1.3	13
95	Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer. European Journal of Cancer, 2021, 144, 151-161.	1.3	13
96	Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. EJNMMI Research, 2020, 10, 40.	1.1	13
97	Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. Journal of Immunotherapy, 2019, 42, 208-214.	1.2	12
98	Adjuvant treatment for melanoma in clinical practice â€“ Trial versus reality. European Journal of Cancer, 2021, 158, 234-245.	1.3	12
99	Discontinuation of <scp>antiâ€PD</scp>â€1 monotherapy in advanced melanomaâ€”Outcomes of daily clinical practice. International Journal of Cancer, 2022, 150, 317-326.	2.3	12
100	Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. Journal of Clinical Oncology, 2022, 40, 9501-9501.	0.8	12
101	Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Critical Reviews in Oncology/Hematology, 2011, 80, 264-277.	2.0	11
102	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 2018, 29, 579-588.	0.7	11
103	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 2018, 29, 572-578.	0.7	11
104	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers, 2020, 12, 1176.	1.7	11
105	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	1.7	11
106	Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, e133-e134.	0.8	10
107	Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis. Annals of Surgical Oncology, 2021, 28, 3951-3960.	0.7	10
108	Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response. Acute Cardiac Care, 2006, 8, 41-45.	0.2	9

#	Article	IF	Citations
109	Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible. Annals of Surgical Oncology, 2021, 28, 5194-5204.	0.7	9
110	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 2021, 13, 4639.	1.7	9
111	A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. Journal of Medical Case Reports, 2010, 4, 10.	0.4	8
112	Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. Journal of Nuclear Medicine, 2016, 57, 96S-104S.	2.8	8
113	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 925-933.	2.0	8
114	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research, 2018, 28, 326-332.	0.6	8
115	Value of screening and followâ€up brain MRI scans in patients with metastatic melanoma. Cancer Medicine, 2021, 10, 8395-8404.	1.3	8
116	Effect of vemurafenib on a V600R melanoma brain metastasis. European Journal of Cancer, 2013, 49, 1795-1796.	1.3	7
117	Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients. Acta OncolÃ³gica, 2019, 58, 1640-1647.	0.8	7
118	Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16Î±-[18F]Fluoro-17Î²-Estradiol PET in a Patient With Estrogen Receptorâ€“Positive Breast Cancer. Clinical Nuclear Medicine, 2021, 46, e165-e167.	0.7	7
119	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Research, 2022, 32, 460-468.	0.6	7
120	In Vivo Quantification of ERÎ² Expression by Pharmacokinetic Modeling: Studies with ¹⁸F-FHNP PET. Journal of Nuclear Medicine, 2017, 58, 1743-1748.	2.8	6
121	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. Cancer Immunology, Immunotherapy, 2021, 70, 3123-3135.	2.0	6
122	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. Melanoma Research, 2021, 31, 58-66.	0.6	6
123	Combination of Vascular Endothelial Growth Factor (VEGF) and Thymidine Phosphorylase (TP) to Improve Angiogenic Gene Therapy. Angiogenesis, 2003, 6, 185-192.	3.7	5
124	Functional Characteristics of Coronary Vasomotor Function Following Intramyocardial Gene Therapy with Naked DNA Encoding for Vascular Endothelial Growth Factor165. Endothelium: Journal of Endothelial Cell Research, 2005, 12, 103-106.	1.7	5
125	Retrospective Denial as A Coping Method. Journal of Clinical Psychology in Medical Settings, 2011, 18, 65-69.	0.8	5
126	Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli etÂal. Arthritis Care and Research, 2018, 70, 1275-1275.	1.5	5

#	Article	IF	Citations
127	Image Quality and Interpretation of [18F]-FES-PET: Is There any Effect of Food Intake?. Diagnostics, 2020, 10, 756.	1.3	4
128	Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer. Diagnostics, 2021, 11, 2019.	1.3	4
129	Influence of p53 Status on the HSV-Tk/GCV-Induced Bystander Effect in a Panel of Human Ovarian Carcinoma Cell Lines. Oncology Research, 2005, 15, 151-159.	0.6	3
130	Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases. BMC Cancer, 2022, 22, 247.	1.1	3
131	Interpreting the RAPIDO trial: factors to consider â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e90-e91.	5.1	2
132	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. Journal of Geriatric Oncology, 2021, 12, 1031-1038.	0.5	2
133	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 82-89.	0.6	2
134	Abstract 4768: Frequency and prognostic value of hormone receptor expression in epithelial ovarian cancer.. , 2013, , .		2
135	FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.. Journal of Clinical Oncology, 2015, 33, 527-527.	0.8	2
136	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 11553-11553.	0.8	2
137	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. Journal of Clinical Oncology, 2016, 34, 9526-9526.	0.8	2
138	Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen. Vaccine, 2009, 28, 386-391.	1.7	1
139	Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. Gastric Cancer, 2010, 13, 95-100.	2.7	1
140	Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients. American Journal of Surgery, 2016, 212, 89-95.	0.9	1
141	Clinical selection strategy for and evaluation of intra-operative brachytherapy in patients with locally advanced and recurrent rectal cancer. Radiotherapy and Oncology, 2021, 159, 91-97.	0.3	1
142	Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	1.7	1
143	Off-Label Prescription of Genetically Modified Organism Medicines in Europe: Emerging Conflicts of Interest?. Human Gene Therapy, 2014, 25, 893-896.	1.4	0
144	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. OncoImmunology, 2019, 8, 1558664.	2.1	0

#	Article	IF	Citations
145	O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS). Ecological Management and Restoration, 2019, 32, .	0.2	0
146	Abstract PS3-05: Value of [18F]-FES-PET to solve clinical dilemmas in breast cancer patients: A retrospective study. , 2021, , .		0
147	OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era. Neuro-Oncology Advances, 2021, 3, iii14-iii14.	0.4	0
148	Preoperative chemoradiotherapy (CRT) in gastric cancer.. Journal of Clinical Oncology, 2013, 31, 89-89.	0.8	0
149	Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma: The TRAP study.. Journal of Clinical Oncology, 2016, 34, TPS4142-TPS4142.	0.8	0
150	Impact of current â€œinsufficientâ€•clinical nodal staging on treatment decisions and response to neoadjuvant chemoradiotherapy in esophageal cancer patients.. Journal of Clinical Oncology, 2017, 35, 111-111.	0.8	0
151	Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.. Journal of Clinical Oncology, 2020, 38, 10032-10032.	0.8	0
152	Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.. Journal of Clinical Oncology, 2022, 40, 9546-9546.	0.8	0
153	Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials.. Journal of Clinical Oncology, 2022, 40, 9577-9577.	0.8	0